Development of Bentrio™ (AM-301) has been completed. The product has been introduced to the market, starting in selected countries of the European Union.
SARS-CoV-2 protection in human nasal epithelium model
Daily treatment with Bentrio™ for 4 days starting 10 minutes prior to inoculation
SARS-CoV-2 treatment in human nasal epithelium model
Daily treatment with Bentrio™ for 4 days starting 24 or 30 hours after inoculation
Prevention / treatment of H1N1 infection in human nasal epithelium model
Daily treatment with Bentrio™ for 4 days starting after inoculation
Protection against symptoms of allergic rhinitis under grass pollen challenge
Exposure of patients with history of allergic rhinitis to grass pollen for four hours, treated prior with either Bentrio™ or HPMC powder nasal spray (n=36)
Prevention / treatment of SARS-CoV-2
Treatment of patients with confirmed Covid-19 and non-infected household members with Bentrio™ or placebo (n=592)
Preventive use of Bentrio™ reduces SARS-CoV-2 titer by up to 99.4%.
Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium model with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 10 minutes prior to inoculation and continued once daily. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >99% on Days 3 and 4. Even when unbound virus was not removed daily through washing, the reduction in viral titer was >92.4% compared to saline-treated controls.
Bentrio™ alleviates allergic rhinitis symptoms.
Mean change in the Total Nasal Symptom Score (TNSS) during stay of study participants with history of allergic rhinitis in grass pollen challenge chamber. A single dose of Bentrio™ applied into each nostril prior to entering the chamber provided for a significant reduction in the self-rated TNSS.